Mozobil
Phase 2Small molecule
Mozobil is one of 33 small molecule programs targeting Beta-Thalassemia Major. It is currently in Phase 2.
3
Indications
6
Total Trials
2
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Mozobil
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Radiotherapy1 trial
A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy
Withdrawn·—·Phase 1·NCT03612466
Beta-Thalassemia Major1 trial
Stem Cells1 trial
1 more indication
Leukopenia1 trial
A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT00967785·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mozobil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details